Novo Nordisk reports 9% net profit increase
Novo Nordisk has reported net profit increased by 9% to Eur 5,1 billion. Diluted earnings per share increased by 11% to Eur 2,01.
Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk has reported net profit increased by 9% to Eur 5,1 billion. Diluted earnings per share increased by 11% to Eur 2,01.
Diplomat Pharmacy has concluded the purchase of a Houston based pharmacy and infusion services specialist Affinity Biotech, which focuses on treating patients with hemophilia.
Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.
Allergan has completed the $2.9 billion purchase of Acelity’s subsidiary LifeCell, adding commercial products to its regenerative medicine portfolio, and LifeCell’s innovative manufacturing capabilities and its R&D operations, based in New Jersey.
Data Monitoring Committee (DMC) held its fourth and final scheduled meeting and recommended continuation of the ongoing randomized, double-blind phase IIa study of Medivir’s MIV-711 in patients with moderate knee osteoarthritis.
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).
INEOS Styrolution, the global player in styrenics, has announced two new styrenics grades, both of which designed for very specific use by medical device manufacturers.
Pharmapack 2017, kicking off on February 1, 2017 marks 20 years of Pharmapack. We talked with Anne Schumacher, Brand Director at Pharmapack Europe.
Allergy Therapeutics, a pharmaceutical company specialising in allergy vaccines, has announced positive results from preclinical research of its therapeutic peanut allergy vaccine, Polyvac Peanut.
Sanofi announced on Wednesday two approvals for its drugs in North America. Rheumatoid arthritis drug, which it has made in cooperation with Regeneron Pharmaceuticals, has been approved by Health Canada and the U.S. Food and Drug Administration (FDA) has approved Xyzal Allergy 24HR